[{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/spikes/rcc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tivozanib\" }]"}]},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/rcc.ts","type":"changed","fields":[{"field":"tldr","before":"\"A highly selective VEGF-receptor pill for kidney cancer after two or more prior treatments, notable for its tolerability and for a trial that closed the door on immunotherapy rechallenge.\"","after":"\"Tivozanib is a highly selective VEGF-receptor pill for kidney cancer after two or more prior treatments, notable for its tolerability and for a trial that closed the door on immunotherapy rechallenge.\""}]},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/rcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]